The ARIEL4 Phase III clinical trial was a randomized, controlled, open-label study that sought to evaluate the efficacy of rucaparib as an alternative treatment option to chemotherapy for patients with relapsed, BRCA1/2-mutated ovarian cancers (Kristeleit et al., 2022). Here, BRCA1 is linked to ovarian carcinoma.